Skip to content
Head to head

NewAmsterdam Pharma vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: NAMS · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

NAMS -52.3%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
NAMSVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price18.41515.02
Change today-5.64%-1.08%
1-year return-51.2%+22.0%
Market cap$2.21B$130.58B
52-week range17.90 – 42.21412.27 – 568.67
Valuation
P/E (TTM)-10.8933.14
P/E percentile, own 5-yr range27th99th
P/B3.506.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.7215.32
Net profit (TTM)$-206.28M$3.88B
Revenue (TTM)$25.94M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+5406.9%+11.8%
Gross margin--85.5%
Operating margin-900.1%33.1%
Net margin-789.9%30.7%
Free cash flow (TTM)$-150.86M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership108.7%96.8%
Insider activity (12mo)24 buy / 26 sell28 buy / 22 sell
Short interest (% of float)10.0%1.9%
Analyst consensus100% buy (10)95% buy / 5% hold (21)
Analyst price target$54 (+196%)$624 (+21%)
StockVane view
StockVane Quant RatingE (5)C (68)
Company
Employees1006,400
Founded20221989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.